Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Registration-Marketing Linkage Row in India

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - With India's drug quality regulator announcing its intention to link giving marketing approval for a drug to its patent status, domestic pharmaceutical companies are up in arms against the move, while multinational firms have welcomed it

You may also be interested in...



Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals

With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies

Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals

With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies

Indian Court Restrains Cipla From Exporting Generic Tarceva

NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said

Related Content

UsernamePublicRestriction

Register

SC068476

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel